These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18991590)

  • 1. In vitro cytochrome P450 inhibition and induction.
    Walsky RL; Boldt SE
    Curr Drug Metab; 2008 Nov; 9(9):928-39. PubMed ID: 18991590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction and inhibition of cytochrome P450 and drug-metabolizing enzymes by climbazole.
    Kobayashi Y; Suzuki M; Ohshiro N; Sunagawa T; Sasaki T; Oguro T; Tokuyama S; Yamamoto T; Yoshida T
    Biol Pharm Bull; 2002 Jan; 25(1):53-7. PubMed ID: 11824557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations.
    Hewitt NJ; Lecluyse EL; Ferguson SS
    Xenobiotica; 2007; 37(10-11):1196-224. PubMed ID: 17968743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of Cytochrome P450 Enzyme Induction and Inhibition in Human Hepatoma Cells.
    Rodrigues RM; De Kock J; Doktorova TY; Rogiers V; Vanhaecke T
    Methods Mol Biol; 2015; 1250():279-85. PubMed ID: 26272150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.
    Huwyler J; Wright MB; Gutmann H; Drewe J
    Curr Drug Metab; 2006 Feb; 7(2):119-26. PubMed ID: 16472102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes.
    Tanaka E
    J Clin Pharm Ther; 1998 Dec; 23(6):403-16. PubMed ID: 10048501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of human hepatocytes to investigate drug metabolism and CYP enzyme induction.
    Klieber S; Torreilles F; Guillou F; Fabre G
    Methods Mol Biol; 2010; 640():295-308. PubMed ID: 20645059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
    Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
    Brandon EF; Meijerman I; Klijn JS; den Arend D; Sparidans RW; Lázaro LL; Beijnen JH; Schellens JH
    Anticancer Drugs; 2005 Oct; 16(9):935-43. PubMed ID: 16162970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
    Kanebratt KP; Andersson TB
    Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
    Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
    Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro techniques for studying drug metabolism.
    Guengerich FP
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):521-33. PubMed ID: 9131489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.
    Nettleton DO; Einolf HJ
    Curr Top Med Chem; 2011; 11(4):382-403. PubMed ID: 21320066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
    Kalgutkar AS; Obach RS; Maurer TS
    Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
    Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
    Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach.
    Rodrigues AD
    Drug Metab Lett; 2007 Jan; 1(1):31-5. PubMed ID: 19356015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure in drug development: the role of inhibition and induction of cytochrome P450 enzymes.
    Hengstler JG; Bolt HM
    Arch Toxicol; 2008 Oct; 82(10):665-6. PubMed ID: 18751968
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo.
    Sahi J; Stern RH; Milad MA; Rose KA; Gibson G; Zheng X; Stilgenbauer L; Sadagopan N; Jolley S; Gilbert D; LeCluyse EL
    Drug Metab Dispos; 2004 Dec; 32(12):1370-6. PubMed ID: 15333513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.